Dysfunctional signaling underlying endometriosis: current state of knowledge

Yeon Jean Cho1,2, Seung Hyun Lee1, Jung Woo Park1, Myoungseok Han1, Mi Jin Park2 and Sang Jun Han2,3,4,5

1Department of Obstetrics and Gynecology, Dong-A University, College of Medicine, Busan, Republic of Korea
2Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA
3Center for Reproductive Medicine, Baylor College of Medicine, Houston, Texas, USA
4Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA
5Center for Drug Discovery, Baylor College of Medicine, Houston, Texas, USA

Correspondence should be addressed to S J Han: sjhan@bcm.edu

Abstract

Endometriosis is defined as the presence of endometrial tissue outside the uterine cavity. It affects approximately 5–10% of women of reproductive age. Endometriosis is associated with dysmenorrhea, dyspareunia and, often, severe pelvic pain. In addition to pain, women with endometriosis often experience infertility. Defining the molecular etiology of endometriosis is a significant challenge for improving the quality of women’s lives. Unfortunately, the pathophysiology of endometriosis is not well understood. Here, we summarize the potential causative factors of endometriosis in the following three categories: (1) dysregulation of immune cells in the peritoneal fluid and endometriotic lesions; (2) alteration of apoptotic signaling in retrograde menstrual tissue and cytotoxic T cells involved in endometriosis progression and (3) dysregulation of oxidative stress. Determining the molecular etiology of these dysregulated cellular signaling pathways should provide crucial clues for understanding initiation and progression of endometriosis. Moreover, improved understanding should suggest new molecular therapeutic targets that could improve the specificity of endometriosis treatments and reduce the side effects associated with current approaches.

Key Words
- endometriosis
- inflammation
- apoptosis
- oxidative stress
- estrogen receptor

Introduction

Endometriosis, defined as the presence of endometrial tissue outside the uterine cavity, results in severe pelvic pain and infertility in up to 5–10% of women of reproductive age (Eskenazi & Warner 1997, Giudice 2010). Understanding the molecular etiology of endometriosis is essential to providing better treatment for this disease. There are many unresolved side effects of treatment, including adverse consequences for normal reproductive function, because current systemic estrogen deficiency therapy using gonadotropin-releasing hormone agonists (Descamps & Lansac 1998), oral contraceptives, synthetic progestins and/or aromatase inhibitors prevents pregnancy (Attar & Bulun 2006). To minimize these side effects, new and essential pathological pathways involved in endometriosis and endometriosis-associated dysfunction need to be evaluated.

There are several hypotheses regarding how endometriosis is initiated and progresses (Bulun 2009). The most widely accepted hypothesis involves retrograde menstruation (Sampson’s hypothesis), wherein viable endometrial tissue fragments move into the pelvic cavity through the fallopian tubes during menstruation (Sampson 1927). These refluxed endometrial cells subsequently adhere to various tissues (such as the ovary, peritoneum,
intestine and uterus), invade them and then proliferate until they become endometriotic lesions. Abnormalities of the genital tract, genetic predispositions, hormonal imbalances, altered immune surveillance, inflammatory responses and abnormal regulation of endometrial cells are potential causative drivers of endometriosis progression (Sourial et al. 2014). Although numerous studies have sought to determine the causative factors underlying the initiation and progression of endometriosis, the precise pathogenesis of endometriosis remains unknown. To help address this crucial question, we have summarized how the dysregulation of inflammation, apoptosis and oxidative stress signaling in immune cells, endometriotic lesions and peritoneal fluid drives the initiation and progression of endometriosis (Gupta et al. 2006, Barrier 2010, Taniguchi et al. 2011). A review of the literature was conducted to identify the most relevant studies reported in the English language. We searched the PubMed MEDLINE electronic database (https://www.ncbi.nlm.nih.gov/pubmed) for articles published between 1996 and 2017. The major keywords used were as follows: ‘endometriosis and inflammation’, ‘endometriosis and immune dysregulation’, ‘endometriosis and apoptosis’ and ‘endometriosis and oxidative stress’. Here, our goal was to present relevant research related to the pathophysiology of endometriosis, and we considered both in vitro studies using human samples and animal model studies. To specify our purpose, we have included additional keywords as follows: ‘T-cell/B-cell dysfunction’, ‘macrophage’, ‘natural killer cells’, ‘cytokine signal’ and ‘inflammation and estrogen receptor’ along with endometriosis. Moreover, references in each article were searched to identify studies potentially overlooked in our initial search.

**Dysregulation of immune signaling during endometriosis progression**

During each menstrual cycle, viable endometrial fragments are transported into the peritoneal area by retrograde menstruation. Several studies have indicated that endometriosis patients have dysregulated immune systems that allow retrograde menstrual tissue to survive. For example, endometriosis patients have elevated levels of activated macrophages, T and B cells, but reduced levels of cytotoxic natural killer (NK) cells compared to healthy women (Jeung et al. 2016). They also show significant upregulation of stem cell growth factor b (SCGFB), interleukin (IL) 8, human growth factor (HGF) and monocyte chemoattractant protein 1 (MCP1) and downregulation of IL13 (Jorgensen et al. 2017). These dysregulated immune cells and their cytokine networks could stimulate the initiation and progression of endometriosis.

**Alterations of macrophages and their cytokine profiles in endometriosis**

Macrophages, the internal components of the mononuclear phagocyte system, are derived from bone marrow progenitors and enter the bloodstream as monocytes. In peripheral tissues, macrophages are matured and activated in response to various external stimuli (such as lineage-determining growth factors, T helper (Th) cell cytokines and microbial products) to modulate the immune system (Santanam et al. 2002).

**Are macrophages required for the progression of endometriosis?**

Significantly increased numbers of macrophages are detected in eutopic endometria in women with endometriosis (Berbic et al. 2009), raising questions regarding their role during endometriosis progression. A rat endometriosis model showed that macrophage depletion using liposomal alendronate (LA) effectively inhibited the initiation and growth of endometriotic lesions, as determined by reduced implantation rates, adhesion scoring, implant size and weight and numbers of infiltrating macrophages in implants following LA treatment compared to vehicle treatment (Haber et al. 2009). Another study revealed that endometrial fragments adhered to and implanted in the peritoneal wall, whereas endometriotic lesions failed to organize and develop in the absence of macrophages because blood vessels failed to reach the inner layers of endometriotic lesions, which subsequently stopped growing (Bacci et al. 2009). These observations suggest an important role for macrophages in endometriosis progression.

**How do macrophages drive endometriosis progression?**

As macrophages secrete various cytokines to modulate normal cell functions, dysregulated macrophage-secreted cytokines have been associated with several diseases (Arango Duque & Descoteaux 2014). An abundance of peritoneal neutrophils and macrophages in the peritoneal fluid of endometriosis patients increases the levels of vascular endothelial growth factor (VEGF), which stimulates endometriosis progression (Lin et al. 2006). Higher
levels of macrophages may play a role in endometriosis by increasing the levels of cytokines responsible for amplifying the angiogenic signal. Interleukin 24 (IL24) is a novel tumor suppressor gene active in a broad range of human cancer cells. In decidual stromal cells, IL24 also significantly restricts the stimulatory effects of estrogen (Shao et al. 2013). Interestingly, macrophages markedly reduce the expression of IL24 in endometrial stromal cells to limit the inhibitory effects of IL24 on cell viability and invasion, as well as on the expression levels of the proliferation-related gene Ki-67, proliferating cell nuclear antigen (PCNA) and cyclooxygenase 2 (COX2) (Shao et al. 2016). Macrophage-mediated downregulation of IL24 leads to the increased proliferation and invasiveness of endometrial stromal cells and contributes to endometriosis progression.

Tumor growth factor (TGF)β levels are also elevated in endometriotic lesions and macrophages in women with endometriosis compared to healthy women (Omwandho et al. 2010). TGFβ-mediated autocrine and paracrine signaling in peritoneal macrophages plays an essential role in endometriosis progression by stimulating macrophage DNA synthesis, macrophage cell–cell interactions and the expression of macrophage cell surface adhesion molecules, such as integrin-α/β (Dou et al. 1997).

**Is there any difference in the macrophage populations between the normal endometrium and endometriotic lesions?**

Macrophages are activated into classic (M1) or alternative (M2) phenotypes depending on the type of stimulation (Martinez & Gordon 2014). Lipopolysaccharides (LPS), interferon-γ (IFN-γ) and granulocyte-macrophage colony-stimulating factor (GM-CSF) induce macrophages toward the M1 phenotype. M1 macrophages produce significant levels of pro-inflammatory cytokines, such as IL1β, tumor necrosis factor (TNF), IL12, IL18 and IL23 (Wang et al. 2014a). These help drive antigen-specific Th1 and Th17 cell inflammatory responses that suppress tumor cell growth (Roberts et al. 2015). In addition to pro-inflammatory cytokines, M1 macrophages upregulate the expression of intracellular protein suppressor of cytokine signaling 3 (SOCS3) and activate inducible nitric oxide synthase (NOS2 or iNOS) to produce NO from L-arginine and inhibit tumor growth (Arnold et al. 2014). Macrophages are guided toward the M2 type by fungal cells, immune complexes, helminth infections, complement components, apoptotic cells, macrophage colony-stimulating factor (MCSF), IL4, IL13, IL10 and transforming growth factor (TGF)-β (Martinez & Gordon 2014). Activated M2 macrophages secrete high levels of IL10, IL1, IL1ra and IL6 to stimulate tumor growth (Arango Duque & Descoteaux 2014).

A rhesus macaque model of endometriosis revealed that, compared to controls, the activation state of macrophages in endometriosis tissues in nonhuman primates was skewed toward the M2 phenotype (Smith et al. 2012). Large peritoneal macrophages (LPMs) and small peritoneal macrophages (SPMs) have been found to polarize toward either M1 or M2 cells, respectively, in a murine model. Accordingly, the proportion of SPMs increased immediately after peritoneal injection of endometrial tissue, whereas LPMs exhibited the opposite trend (Yuan et al. 2017). Thus, it is possible that retrograde menstrual tissues could stimulate peritoneal macrophage polarization to the M2 type. In human endometriosis patients, there is high M2 macrophage polarization, and in vitro co-culture analyses have shown that M2 macrophages significantly upregulate proliferation of endometrial stromal cells by activating signal transducer and activator of transcription 3 (STAT3) signaling (Itoh et al. 2013). STAT3 signaling is aberrantly activated in epithelial and endometrial stromal cells in human endometriotic lesions (Kim et al. 2015). Therefore, endometriosis-associated M2 macrophages may stimulate STAT3 signaling in endometriotic lesions and thereby stimulate endometriosis.

**What causative factors drive M2 macrophage polarization in endometriotic cells?**

M2 macrophage polarization is regulated by the endometrium. Abnormal expression of indoleamine 2,3-dioxygenase-1 (IDO1) in endometrial stromal cells promotes an inflammatory response that subsequently initiates M2 macrophage polarization, which may facilitate the survival of retrograde menstrual tissues (Mei et al. 2017). Fractalkine (FKN), which is secreted by eutopic endometrial stroma cells, also stimulates M2 macrophage polarization and enhances endometriosis progression (Wang et al. 2014b). FKN induces M2 macrophage polarization by decreasing CD86 expression. In addition, FKN increases the expression of matrix metalloproteinase 9 (MMP9) by decreasing the expression of tissue inhibitor of MMP1 and 2. This promotes the invasiveness of endometrial stromal cells by activating p38 mitogen-activated protein kinases (MAPKs) and the integrin β1 signaling pathway to stimulate endometriosis progression (Collette et al. 2006, Wang et al. 2014b).
Exposure to endocrine-disrupting chemicals interferes with the endocrine system, causing cancers, tumors, birth defects and other developmental disorders, resulting in the progression of several human diseases (Mallozzi et al. 2017, Ribeiro et al. 2017). For example, exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) compounds stimulate endometriosis progression (Smart et al. 2016). To induce endometriosis, TCDD alters patterns of macrophage activation. Combining 17β-estradiol with TCDD has a synergistic effect on the induction of M2 macrophage activation when macrophages are co-cultured with endometrial stromal cells, because it activates STAT3 and p38 MAPK signaling pathways (Wang et al. 2015). In addition to in vitro assays, the combination of TCDD and high levels of local 17β-estradiol in endometriotic lesions has been shown to synergistically induce M2 macrophage polarization and stimulate endometriosis in humans (Delvoux et al. 2009).

Annexin A2 is involved in various cellular processes, such as cell motility, cytoskeletal regulation and endocytosis. Levels of annexin A2 are markedly reduced in peritoneal macrophages from women with endometriosis compared to controls, and downregulation of annexin A2 inhibits the phagocytic capacity of macrophages (Wu et al. 2013). The level of annexin A2 mRNA in macrophages is reduced by prostaglandin E2 (PGE2) via the EP2/EP4 receptor-dependent signaling pathway. Indeed, elevated levels of PGE2 have been detected in endometriotic lesions (Rakhila et al. 2015), where they may reduce the ratio of M1/M2 peritoneal macrophages and stimulate the progression of endometriosis.

Endometriotic lesions exhibit high levels of the C–C chemokine regulated on activation, normal T-cell expressed and secreted (RANTES). During osteogenesis, RANTES stimulates the transition of M1 to M2 macrophages in osteoprogenitors (Cordova et al. 2017). Elevated RANTES levels has been linked to endometriosis progression (Hornung et al. 2001, Wang et al. 2010) and is likely involved in M2 peritoneal macrophage polarization in endometriosis patients. TCDD promotes RANTES expression, and a combination of 17β-estradiol and TCDD significantly enhanced RANTES secretion in an endometriosis-associated human endometrial cell co-culture system, recruiting greater numbers of macrophages (Wang et al. 2010). RANTES could be a molecular therapeutic target for endometriosis, as suggested by the action of shikonin, an anti-inflammatory phytocompound derived from Lithospermum erythrorhizon, that mediates the inhibition of RANTES secretion and reduces endometriosis progression (Yuan et al. 2014).

The activation of TGFβ signaling in endometriosis also induces M2 macrophage polarization to stimulate inflammatory signaling and tissue repair (Gong et al. 2012).

Dysregulation of T-cell-mediated cytokine profiling in endometriosis

Lymphocyte subpopulations in endometriotic lesions are markedly different from those in normal endometrial tissue. Specifically, endometriotic lesions display increased numbers of CD4 and CD8 cells and activated T cells compared to normal endometrial tissue (Witz et al. 1994). Additionally, T-cell subtypes are also differentially regulated. The proportion of Th1 lymphocytes is significantly lower, whereas the Th17 lymphocyte fraction is significantly elevated in endometriotic lesions (Takamura et al. 2015). One recent study has shown that IL-10+Th17 cell population is significantly elevated in the peritoneal fluid of endometriosis patients as compared to the women without endometriosis (Chang et al. 2017). Interestingly, elevation of IL-10+Th17 cell population is associated with increased levels of IL-27, IL-6 and TGF-β. Especially, TGF-β stimulates IL-10 production in Th17 cells in vitro and in vivo in human endometrial stromal cells to stimulate the proliferation and implantation of ectopic lesions and accelerate the progression of endometriosis (Chang et al. 2017). Although these patterns are not fully understood, this differential T lymphocyte activation appears to clearly be involved in the pathophysiology of endometriosis.

Altered ratios of Th1/Th2 cells in endometriotic lesions

CD4+ T lymphocytes, or Th cells, can be further subdivided into Th1 and Th2 cells, and the cytokines they produce are referred to as Th1-type and Th2-type, respectively (Berger 2000). Th1-type cytokines tend to generate pro-inflammatory responses, whereas Th2-type cytokines, such as IL-4, IL-5, IL-10 and IL-13, tend to elicit anti-inflammatory responses. A well-balanced Th1 and Th2 response is important for various immune challenges (Berger 2000). In endometriotic lesions, the levels of IFN-γ, IL10 and the ratios of IL4/IFN-γ, IL4/IL2 IL10/IFN-γ, and IL10/IL2 are significantly elevated in the peritoneal fluid of endometriosis patients compared to healthy controls (Podgaec et al. 2007), which reflects a shift toward the Th2 immune response. Endometriosis progression may be associated with a reduced Th1/Th2 ratio among T cells in the peritoneal fluid.
Role and determinants of Th2 cytokine production during endometriosis progression

In humans, cytokines secreted from Th2 cells stimulate endometriosis progression. For example, IL4, a typical Th2 cytokine, has been shown to increase the mRNA expression of 3β-hydroxysteroid dehydrogenase (HSD3B2) in a dose-dependent manner (Urata et al. 2013). HSD3B2 is a pivotal enzyme for estrogen production. IL4 increases local estrogen levels to stimulate endometriosis progression. In addition, IL4 increases the proliferation of endometriotic stromal cells by activating p38 MAPK, stress-activated protein kinase/c-Jun kinase and p42/44 MAPK to stimulate endometriosis progression (OuYang et al. 2008b). Similar changes have been observed in mouse models. The weights and areas of endometriotic lesions have been found to be significantly reduced following treatment with INF-γ and IL2 (Th1 cytokines) compared to treatment with IL4 and IL10 (Th2 cytokines) or saline solution (controls) (Mier-Cabrera et al. 2013). Th1 cytokine milieu suppress the progression of endometriosis in a murine endometriosis model.

Eutopic endometrial tissues from patients with endometriosis have higher mRNA levels of GATA-binding protein 3 (GATA3) compared to normal endometrial tissue (Chen et al. 2012). Expression of GATA3 is regulated by estrogen, and their synergistic action regulates Th2 cytokine (e.g., IL6, IL8 and IL10) expression in eutopic endometrial cells (Chen et al. 2016). Therefore, GATA3 integrates estrogen signaling to induce Th2 cytokine expression in endometriotic lesions, thereby promoting endometriosis progression.

IL6 levels are also elevated in endometrial stromal cells isolated from women with endometriosis compared to healthy controls (Tsudo et al. 2000). IL6 expression in endometriotic cells is induced by IL1β and TNF-α (Akoum et al. 1996). IL6 promotes CD4+ Th2 differentiation and inhibits Th1 differentiation via two independent molecular mechanisms (Diehl et al. 2000). Elevated IL6 levels promote Th2 differentiation by activating transcription mediated by nuclear factor of activated T cells (NFAT) (Diehl & Rincon 2002). Additionally, IL6 inhibits Th1 differentiation by interfering with IFN-γ signaling and the expression of suppressor of cytokine signaling 1 (SOCS1). These findings may support a role for IL6 in Th2 differentiation and Th2 cytokine production in endometriotic lesions.

Alteration of Treg cells in endometriosis

In addition to Th1 and Th2 cells, naïve T cells can differentiate into regulatory T (Treg) cells (Josefowicz et al. 2012). Treg cells suppress a range of immune responses, such as T-cell proliferation and activation (Giatromanolaki et al. 2008), as well as macrophage, B-cell, dendritic cell and NK-cell function (Thornton 2005). Because of its immunosuppressive function, the infiltration of large numbers of Treg cells into tumor tissues is associated with a poor prognosis (Enokida & Nishikawa 2017). Consistent with tumor progression, a higher concentration of Treg cell phenotypes and/or expression markers has been detected in peritoneal fluid and endometriotic lesions but not in samples from healthy control women (Bellelis et al. 2013, Slabe et al. 2013, de Barros et al. 2017). To initiate and establish endometriosis, retrograde menstrual tissues in the peritoneal region must escape the host immune surveillance system. To achieve this, the large numbers of Treg cells in the T-cell population and endometriotic lesions decrease the recruitment of immune cells to prevent the recognition and targeting of retrograde menstrual tissues, thus allowing their survival and implantation into ectopic sites.

Th17 cells and IL23 levels in endometriosis

In addition to Th2 cytokines, the levels of IL23 and the Th17 cytokine IL17 are highly elevated in the peritoneal fluid of women with minimal or mild endometriosis (Andreoli et al. 2011). Th17 cells are involved in the pathogenesis of several autoimmune diseases, and endometriosis is associated with a higher risk (20–60%) of autoimmune disease, such as multiple sclerosis, systemic lupus erythematosus and Sjögren syndrome (Ouyang et al. 2008a, Nielsen et al. 2011). In vitro stimulation of endometrial epithelial carcinoma cells, Ishikawa cells and HUVECs with IL17A revealed that IL17A treatment significantly increased angiogenic (VEGF and IL8), pro-inflammatory (IL6 and IL1β) and chemotactic cytokine levels (G-CSF, CXCL12, CXCL1 and CX3CL1) (Ahn et al. 2015). The levels of IL23 were significantly higher in the peritoneal fluid of women with endometriosis compared to normal controls (Andreoli et al. 2011). Activated naïve T cells produce IL23, which then increases the levels of IL10 and IL17, both of which are required for endometriosis progression (Vanden Eijnden et al. 2005). Dysregulation of IL23 is also involved in several endometriosis-associated endometrial dysfunctions, such as infertility (Andreoli et al. 2011, Frazer et al. 2013).

Altered T-cell activation and autoimmune properties of endometriosis

Endometriosis is not itself an autoimmune disease; however, women with endometriosis may have been reported to
have a higher risk of developing several autoimmune diseases, such as systemic lupus erythematosus, Sjögren’s syndrome, multiple sclerosis and rheumatoid arthritis (Haga et al. 2005, Harris et al. 2016). This is somewhat controversial, however, as another study reported no correlation between them (Nielsen et al. 2011). In many autoimmune diseases, altered activation of CD4+ T cells plays a critical role in activating B cells to stimulate the production of autoantibodies (Palmer & Weaver 2010). Consistent with autoimmune disease, the elevated levels of autoantibodies against the endometrium and ovary are highly elevated in endometriosis patient (Mathur et al. 1982). Therefore, altered activation of CD4+ T cells, as described earlier, might be involved in the elevation of autoimmune disease properties in endometriotic lesions.

Dysfunction of NK cells in endometriosis patients

NK cells secrete lytic granules containing granzyme, perforin and cytotoxins (such as IFN-γ) to destroy other cells (Topham & Hewitt 2009). Cytotoxic NK cells therefore play a critical role in innate immunity to activate the host immune surveillance system following exposure to pathogens. Because of the crucial role of NK cells in innate immunity, dysregulation of NK cells causes immune-related disease progression (Smyth et al. 2005, Mandal & Viswanathan 2015). The levels of molecular markers of cytotoxic NK cells, such as markers of activation (granzyme B, perforin, TRAIL, CD107a and CD69) and cell surface markers (NKp46, NKp44, NKG2D and CD16), are significantly reduced, but the proportion of immature NK cells (CD272CD11b2+) in the NK cell population (CD32CD56+) is elevated in the peritoneal fluid of endometriosis patients compared to normal women (Oosterlynck et al. 1991, Jeung et al. 2016).

How are cytotoxic NK cells downregulated in endometriotic lesions compared to normal endometrial tissue?

Cytokines with inhibitory effects on cytotoxic NK cells, such as inflammatory cytokines (IL6, IL8, IL1β, IFN-γ and TNF-α) and non-inflammatory cytokines (CXCL3, CCL2, CCL5), are significantly elevated in the peritoneal fluid of endometriosis patients compared to controls (Malutan et al. 2015). Moreover, peritoneal fluid from endometriosis patients also shows elevated levels of antigens (HLA-G and HLA-E), immunoreceptor tyrosine-based inhibitory motif killer cell inhibitory receptors (ITIM-KIRs), inhibitory NK cell receptors containing Ig domains (KIR2DL1, KIR3DL1), EB6 and soluble intracellular adhesion molecule-1 (I-CAM), which also suppress cytotoxic NK cells (Jeung et al. 2016). In addition, HLA-G expression is detected in eutopic endometrial tissue of endometriosis patients during the menstrual phase (Thiruchelvam et al. 2015). Retrograde menstrual tissues showed elevated levels of HLA-G in the peritoneal cavity, where they can interact with the immune surveillance system and counteract the cytotoxicity of NK cells. This would allow retrograde menstrual tissues to survive and implant, eventually developing into endometriotic lesions. Therefore, increased levels of inflammatory cytokines, antigens and inhibitory receptors in the peritoneal fluid and endometrium downregulate cytotoxic NK activity during the progression of endometriosis.

Activation of B cells in endometriosis

B cells underlie humoral immune responses by producing antibodies against antigens. Increased numbers of B cells are found in the blood and peritoneal fluids of endometriosis patients compared to healthy women (Osuga et al. 2011). Interestingly, transcriptional factors regulating B-cell function are differentially expressed in endometriosis patients compared to healthy women. For example, B lymphocyte inducer of maturation program (Blimp)-1, which is a crucial regulator of plasma cell differentiation, is significantly increased; the levels of B-cell leukemia lymphoma (Bcl)-6, its antagonist, are significantly reduced in the peritoneal cavities of endometriosis patients (Yeol et al. 2015). In addition to transcription factors, endometriotic lesions also have higher levels of cytokines that activate B cells, such as B lymphocyte stimulator (BLys) (Hever et al. 2007). BLys plays an important role in the normal development of B cells and their differentiation into plasma cells (Schliemann et al. 2001). Therefore, these factors can stimulate B-cell function in endometriosis patients.

These hyperactivated B lymphocytes appear to contribute to the pathogenesis of endometriosis by producing autoantibodies against the endometrium, DNA and phospholipids, as well as antinuclear antibodies (Osuga et al. 2011). A similar elevation of autoantibodies has also been observed in autoimmune diseases (Eggett et al. 2010). Because of the many similarities between endometriosis and autoimmune diseases, endometriosis may be treatable as an autoimmune disease (Nothnick 2001).
Alteration of cytokine profiling in endometriotic lesions

In addition to immune cells, endometriotic lesions are themselves a source of secreted cytokines that stimulate endometriosis progression. For example, endometriotic epithelial cells have increased levels of TNF-α compared to normal endometrial tissue during endometriosis progression. Epithelial TNF-α activates the phosphoinositide 3-kinase (PI3K), MAPK, c-Jun N-terminal kinase (JNK), p38 and IκB kinase signaling pathways via autocrine responses to stimulate inflammation and invasion of endometriotic epithelial cells, thus favoring their proliferation (Grund et al. 2008). Endometriotic epithelial TNF-α also induces IL6 and IL8 expression in endometriotic stromal cells via nuclear factor-kappa-B (NF-κB) and activator protein (AP)1 through paracrine responses to stimulate proliferation of endometriotic stromal cells (Sakamoto et al. 2003, Yamauchi et al. 2004). These dysregulated autocrine or paracrine cytokine signaling networks in endometriotic lesions are also involved in endometriosis progression.

In addition to TNFα, endometriotic lesions are a source of various cytokines, such as ENA78, RANTES, IL6 and IL8 (Akoum et al. 2001, Bertschi et al. 2013). IL6 plays a significant role in CD4+ T-cell differentiation (Dienz & Rincon 2009), and IL8 induces T lymphocyte infiltration in target tissues (Taub et al. 1996). Therefore, IL6 and IL8 in endometriotic lesions might generate T-cell milieus specific for endometriotic lesions to enhance their survival.

Inflammatory and estrogen receptor (ESR) signaling in endometriotic lesions and macrophages

Peritoneal macrophages are activated by exposure to 17β-estradiol (Hong & Zhu 2004). Because a higher activity of the 17β-estradiol axis stimulates endometriosis-associated macrophage activation to synergistically induce endometriosis, endometriosis has been considered an estrogen-dependent inflammatory disease. In addition to higher local estradiol concentrations, ESR levels are also differentially regulated in endometriotic lesions in response to increased estradiol signaling. Accordingly, elevated levels of ESR2 but not ESR1 have been detected in endometriotic tissues compared to normal endometrial tissues. Elevated ESR2 stimulates prostaglandin production in endometriotic tissues through COX2 to promote endometriosis progression (Wu et al. 2010, Bulun et al. 2012). Increased prostaglandin levels suppress the immune system, allowing retrograde menstrual tissues to escape the immune surveillance system and develop into endometriotic lesions. In addition, ESR2 interacts with components of the cytoplasmic inflammasome to increase IL1β in endometriotic lesions, stimulating their adhesion and proliferation properties (Han et al. 2015). Therefore, increases in ESR2 function modulate the immune response to retrograde menstrual tissues, which can subsequently develop into endometriotic lesions. Hypomethylation of the ESR2 gene promoter region might contribute to higher ESR2 levels in endometriotic lesions (Xue et al. 2007), but detailed molecular mechanisms underlying ESR2 function in endometriosis progression remain unclear.

Peritoneal macrophages are activated upon 17β-estradiol treatment to stimulate endometriosis progression (Hong & Zhu 2004), and expression levels of ESR2 are significantly increased in peritoneal macrophages of women with endometriosis (Montagna et al. 2008). Pretreatment of peritoneal macrophages with ERB-041, a selective ESR2 agonist, results in significant inhibition of LPS-induced iNOS expression by suppressing NF-κB activation and endometriosis progression (Harris et al. 2005, Xiu-li et al. 2009). Collectively, the alteration of the ESR2-estradiol axis in macrophages is another driver of endometriosis progression.

Communication between immune cells and endometriotic lesions drives endometriosis progression

We have discussed dysregulated immune signaling in both immune cells and endometriotic lesions. Interestingly, altered inflammatory signaling in immune cells induces endometriotic lesions to enhance endometriosis progression (Fig. 1). During the initiation of endometriosis, altered immune cells release pro-inflammatory cytokines (IL1, IL6, IL8, IL10, IL12, IL13, TNF-α, VEGF and platelet-derived growth factor (PDGF)) by activating the STAT, p38, extracellular signal-regulated kinase (ERK) and JNK signaling pathways. These cytokines bind to their receptors in endometriotic lesions and mediate further downstream signaling via NF-κB to initiate and establish endometriosis progression. For example, mRNA expression levels of steroidogenic acute regulatory protein (StAR), COX2, MMP9 and other pro-inflammatory cytokines is increased in endometriotic lesions as a result of NF-κB-mediated pro-inflammatory cytokines (Tsai et al. 2001). Elevated StAR expression is involved in estradiol production in endometriotic lesions, further promoting endometriosis progression. Moreover, increased local E2 levels directly induce COX2 expression to promote PGE2 production.
and activate inflammasomes via ESR2 to induce IL1β, thus enhancing the adhesion and proliferation of endometriotic lesions and endometriosis progression.

**Dysregulated apoptosis signaling in endometriotic lesions**

Impaired apoptosis in retrograde menstrual tissues and abnormal apoptosis in immune cells are associated with endometriosis progression (Taniguchi et al. 2011). Understanding the molecular mechanisms governing the dysregulation of apoptosis in endometriotic tissues and immune cells is crucial for determining the molecular etiology of endometriosis and providing new molecular therapeutic treatments. Here, we discuss how dysregulated apoptosis is involved in the progression of endometriosis.

**Reduced apoptosis in endometriotic lesions**

Compared to healthy women, apoptosis is significantly reduced in eutopic endometrial tissue in patients with endometriosis (Gebel et al. 1998). Specifically, endometriotic lesions show higher BCL2 (anti-apoptotic signaling) staining than normal endometrial tissue (Harada et al. 2004), as well as increased expression of c-myc (a cell-cycle regulator) and TGF-β; in contrast, reduced levels of the pro-apoptotic BCL2-associated X protein (BAX) are found (Meresman et al. 2000, Vetvicka et al. 2016, Yu et al. 2017). Collectively, the reduction of apoptosis in endometriotic lesions represents a concerted effort by retrograde menstrual tissues to evade immune surveillance and develop into endometriotic lesions.

**Dysregulation of intrinsic apoptosis signaling in endometriosis**

Apoptotic signaling occurs via two different pathways: intrinsic (or mitochondrial) and extrinsic (or death receptor-mediated) (Schleich & Lavrik 2013). Suppression of the intrinsic apoptotic pathway has been detected in endometriotic lesions. The ratio of anti- to pro-apoptotic molecules, such as BCL2/BAX, is higher in mitochondria.
of eutopic endometrial tissues (Meresman et al. 2000) and in macrophages from endometriotic lesions. The BCL2 family of proteins constitutes a critical intracellular checkpoint of the intrinsic apoptotic pathway; increased BCL2 but decreased BAX expression levels are found in the proliferative phase of eutopic endometrial tissues from patients with endometriosis compared with normal endometrial tissue. Women with endometriosis have a large BCL2-positive macrophage population in the peritoneal fluid, whereas women without endometriosis have a peritoneal macrophage population that has elevated levels of BAX (McLaren et al. 1997). Interestingly, the expression profile of apoptosis-related proteins in endometriotic lesions is regulated in a location-dependent manner. For example, p53 and p21 are higher in ovarian endometriosis, whereas BCL2 expression is higher in peritoneal and colorectal endometriosis (Dufournet et al. 2006). A different mechanism of suppression of the intrinsic apoptotic pathway might be involved in the development of each type of endometriotic lesion, and targeting specific anti-apoptotic pathways may be useful as a component of endometriosis treatment for specific endometriotic lesions.

Alteration of extrinsic apoptosis signaling in endometriosis

**Fas/FasL**

The Fas/FasL axis is the traditional extrinsic apoptosis signaling cascade (Curtin & Cotter 2003). Fas (DR2/CD95/Apo-1) is a type I cell membrane protein (mFas), with an extracellular domain that binds FasL (CD95L/CD178/Apo-1L) and a cytoplasmic domain that transduces the death signal (Peter et al. 2007, Strasser et al. 2009). Cell death signaling mediated by the Fas/FasL interaction plays an essential role in the immune system and in maintaining immune-privileged sites in the body. For example, Fas/Fasl-mediated apoptosis kills cytotoxic T cells (Waring & Mullbacher 1999). Fasl is expressed in normal human endometrial cells, where it is stimulated by macrophage cytokines, such as PDGF and TGF-β1 (Garcia-Velasco et al. 1999). Higher levels of IL8 in the peritoneal fluid of endometriosis patients cause an increase in FasL expression in endometrial cells (Selam et al. 2002) and endometrial stromal cells. However, increased Fasl does not induce apoptosis in endometrial stromal cells (Selam et al. 2006a). Ectopic epithelial cells of endometriotic lesions have simultaneously increased FasL expression and reduced Fas expression, irrespective of the menstrual cycle phase (Sbracia et al. 2016). Collectively, induction of FasL in endometrial cells may induce apoptosis in cytotoxic T cells expressing the Fas receptor, thus allowing them to evade immune surveillance and develop into endometriotic lesions.

**TNFα-mediated apoptosis**

Changes in TNF-α-mediated cell death signaling are also involved in endometriosis progression (Iwabe et al. 2000). During retrograde menstruation, the influx of retrograde menstrual tissues into the peritoneal cavity activates macrophages to secrete cytotoxic cytokines, such as TNF-α, inducing apoptosis signaling in extratumoral endometrial fragments that need to be removed (Leavy 2015). In endometriosis patients, however, the molecular properties of retrograde menstrual tissues are altered in a way that allows escape from TNF-α-mediated apoptosis. As endometriosis is an estrogen-dependent disease, nuclear receptor coactivator (NCOA)αs may play an important role in endometriosis progression. Interestingly, endometriotic lesions have an elevated level of the NCOA-1 isoform, but not full-length NCOA-1 (Han et al. 2012). The NCOA-1 isoform is proteolytically generated from full-length NCOA-1 by MMP9 in endometriotic lesions. There, the NCOA-1 isoform, but not full-length NCOA-1, interacts with caspase 8 to prevent TNF-α-mediated apoptosis by disrupting apoptosis complex II formation. Endometriotic lesions also express high levels of ESR2 (Hudelist et al. 2005), which then interacts with caspase 8 or components of the cell death machinery in endometriotic cells to block TNF-α-induced apoptosis (Han et al. 2015). Specifically, high ESR2 induces the formation of apoptosis signal-regulating kinase 1 (ASK1), serine/threonine kinase receptor-associated protein and the 14-3-3 protein complex to inhibit ASK1 activity required for TNF-α-mediated apoptosis. Moreover, ESR2 disrupts apoptosisome formation by interacting with and preventing the activation of caspase 9 in endometriotic lesions. Taken together, induction of the endometriosis-specific NCOA-1 isoform/ESR2 axis actively prevents TNF-α-induced apoptosis signaling in endometriotic lesions by interacting with the apoptotic machinery (Fig. 2).

**Targeting the dysregulation of apoptosis signaling in endometriotic tissues**

In addition to endometriosis progression, the sophisticated regulation of apoptosis also plays an important role in embryonic development via the appropriate formation of various organs and structures (Haanen & Vermes 1996).
Therefore, defective apoptosis signaling during embryogenesis may cause developmental abnormalities (Haanen & Vermes 1996). Dysregulation of apoptosis is a key driver of many human diseases and may serve as an effective molecular therapeutic target for the treatment of many human diseases.

PGE2 levels are elevated in endometriosis patients; PGE2 promotes the survival of human endometriotic lesions through EP2 and EP4 receptors and activation of the ERK1/2, AKT, NF-κB and β-catenin signaling pathways (Banu et al. 2009). Selective inhibitors of EP2 (AH6809) and EP4 (AH23848) suppress these cell survival pathways and enhance interactions between anti-apoptotic and pro-apoptotic proteins, thereby activating the intrinsic apoptotic pathways in human endometriotic cells.

Pro-inflammatory cytokines also regulate apoptotic signaling in various cells to modulate their cellular function (Grunnet et al. 2009). In endometriosis, dysregulated cytokines prevent apoptosis and promote the survival of endometriotic lesions. For example, secretion of CXCL8 is significantly higher in eutopic endometrial stromal cells of women with endometriosis compared to normal endometrial tissues, and elevated CXCL8 reduces apoptosis by upregulating BCL2 expression in these cells in an autocrine manner (Li et al. 2012). Anti-human CXCL8-neutralizing antibodies suppress endometriosis progression by inducing apoptosis in endometriotic lesions. RANTES and IL8 attenuate apoptosis in endometriotic lesions (Selam et al. 2006b); shikonin-mediated inhibition of RANTES secretion reduces endometriosis progression (Yuan et al. 2014). Treatment with an IL8-neutralizing antibody also suppresses endometriosis progression by inhibiting the attachment of retrograde menstrual tissues and reactivating apoptosis in these cells (Arici 2002). Collectively, molecules that induce anti-apoptotic pathways in endometriotic lesions could be molecular therapeutic targets for alternative endometriosis treatments.

**Dysregulation of oxidative stress in endometriosis**

Healthy women exhibit balanced levels of reactive oxygen species (ROS) and antioxidants. An overabundance of ROS induces oxidative stress, impacting women throughout their reproductive lifespan, including in the initiation of endometriosis (Carvalho et al. 2012). Oxidative...
stress results in damage to cellular lipids, proteins and DNA, changing their molecular properties and possibly leading to disease. Importantly, ROS overproduction impairs cellular functions by inducing redox-sensitive transcription factor (such as NF-κB)-mediated expression of genes required for the initiation and progression of endometriosis (Fig. 3) (Defrere et al. 2011).

Erythrocytes, apoptotic endometrial tissue and cell debris transplanted into the peritoneal cavity by menstrual reflux, as well as macrophages, have all been cited as potential inducers of oxidative stress. Iron overload has been detected in the cells and peritoneal fluid of women with endometriosis compared to normal endometrial tissues (Van Langendonckt et al. 2002, Carvalho et al. 2012). Excessive iron induces deleterious ROS in the peritoneal environment, which enhances the attachment and growth of retrograde menstrual tissues (Alizadeh et al. 2015, Donnez et al. 2016). In a murine model, iron overload has been shown to further expand endometriosis by promoting epithelial cell proliferation at lesion sites (Defrère et al. 2006). Additionally, excessive iron levels may favor nitric oxide production, resulting in the impaired clearance of endometrial cells by macrophages (Pirdel & Pirdel 2014). At present, it remains unclear why iron-mediated oxidative stress is maintained at high levels in endometriosis patients compared to healthy women. One possibility is that it is associated with alterations in ROS detoxification pathways and reductions in catalase levels, as observed in cancer patients (Ngo et al. 2009). Retrograde menstruation-mediated hyperactivated oxidative stress leads to stimulation of the ERK and PI3K/AKT/mTOR signaling pathways (Fig. 3), thus promoting adhesion, angiogenesis and proliferation of endometriotic lesions and subsequent endometriosis progression (McKinnon et al. 2016).

Development of alternative endometriosis treatments based on drugs targeting the dysregulated immune system, apoptosis and oxidative stress

The goal of endometriosis treatment is to relieve pain and/or achieve successful pregnancies in infertile patients. Most current medical treatments induce systemic estrogen depletion, because estrogen signaling is an essential driver of endometriosis. However, many current clinical endometriosis treatments are not sufficiently effective and have unacceptable side effects, because the specific molecular etiology of endometriosis has not yet been elucidated. Here, we have discussed endometriosis-associated processes, including dysregulation of inflammation, anti-apoptosis and oxidative stress in endometriosis patients. Therefore, these dysregulated cellular pathways provide...
important clues to understanding the molecular etiology of endometriosis and could offer new molecular therapeutic targets to improve the specificity of endometriosis therapy and reduce side effects of current treatments. Based on these findings, several drugs targeting endometriosis-specific inflammation, anti-apoptosis and oxidative stress pathways, as well as alternative hormonal agents, have been developed and examined using in vitro and in vivo endometriosis models. The most recently studied drugs are summarized in Table 1.

**Table 1**  Emerging medical therapies in endometriosis with human data: alternative hormonal agents as well as agents targeting endometriosis-specific inflammation, anti-apoptosis and oxidative stress.

<table>
<thead>
<tr>
<th>Target site</th>
<th>Drug name</th>
<th>Results in human study</th>
<th>Main effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hormonal agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aromatase inhibitor</td>
<td>Block androstenedione to estrone</td>
<td>Letrozole</td>
<td>Retrospective analysis (Abushahn et al. 2011)</td>
</tr>
<tr>
<td>GnRH antagonist</td>
<td>Direct pituitary gonadotropin suppression</td>
<td>Elagolix</td>
<td>RCT (Taylor et al. 2017)</td>
</tr>
<tr>
<td>SERMs</td>
<td>Nonsteroid selective agonist or antagonist effects in different estrogen target tissues</td>
<td>Raloxifene</td>
<td>RCT (Stratton et al. 2008)</td>
</tr>
<tr>
<td>SPRMs</td>
<td>Progesterone receptor antagonist/agonist</td>
<td>Asoprisnil</td>
<td>RCT (Chwalisz et al. 2005)</td>
</tr>
<tr>
<td>Non-hormonal agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiangiogenic agents</td>
<td>Anti-VEGF antibody</td>
<td>Avastatin</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>3-Hydroxy-3-methyl glutaryl coenzyme A inhibitor</td>
<td>Simvastatin</td>
<td>RCT (Almassinokiani et al. 2013)</td>
</tr>
<tr>
<td></td>
<td>Dopamine receptor 2 agonist COX-2 inhibitors</td>
<td>Quinagolide</td>
<td>Observational study (Gomez et al. 2011)</td>
</tr>
<tr>
<td>antioxidant agents</td>
<td>Epigallocatechin-3-gallate Melatonin</td>
<td>Celecoxib</td>
<td>Case-control study (Cobellis et al. 2004)</td>
</tr>
<tr>
<td></td>
<td>Pentoxifylline</td>
<td>Pentoxifylline</td>
<td>RCT (Schwarter et al. 2013)</td>
</tr>
<tr>
<td>Immunosuppressors</td>
<td>Anti-TNF-α antibody mTOR inhibitor Endogenous eicosanoid, inhibit MMP-9</td>
<td>Infliximab</td>
<td>RCT (Koninckx et al. 2008)</td>
</tr>
<tr>
<td></td>
<td>Rapamycin LXA4</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Apoptotic agent</td>
<td>Natural polyphenolic compound, induce p53 mediated apoptosis</td>
<td>Curcumin</td>
<td>None</td>
</tr>
<tr>
<td>Metformin</td>
<td>Insulin sensitizer from the family of the biguanides</td>
<td>Metformin</td>
<td>None</td>
</tr>
<tr>
<td>MMP inhibitor</td>
<td>Doxycycline ONO-4817</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

SERMs, selective estrogen receptor modulators; SPRMs, selective progesterone receptor modulators; MMP, matrix metalloproteinase.

Conclusion

Retrograde menstruation occurs in all women of reproductive age. For reasons that remain unknown, retrograde menstrual tissues develop into endometriotic lesions in 5–10% of cases. Here, we have discussed how dysregulation of the immune system, apoptosis and oxidative stress are closely associated with endometriosis progression. The dysregulated status of these signaling pathways may predispose women to developing endometriosis, although it remains to be determined what causes such dysregulation in the endometrial tissues to develop into endometriotic lesions. Epigenetic changes caused by nutrition and environmental variables or genetic changes might be potential factors that can initiate endometriosis (Borgese et al. 2017). Moreover, further studies on functional correlation between the dysregulated signals and the severity of endometriosis are clearly needed but, taken together, the dysregulated signals herein we have reviewed may also be connected to disease severity. Future studies must determine how these potential endometriosis initiation factors dysregulate the immune system, apoptosis and oxidative stress pathways, leading to the initiation and progression of endometriosis.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.
Funding
This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, 5 U24 DK097748-04 Pilot Grant), the Mike Hogg Foundation, the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future planning (NRF-2016R1C1B1006876) and the Dong-A University Research Fund (2017).

References
Ahn SH, Edwards AK, Singh SS, Young SL, Lessey BA & Tayade C 2015 IL-17A contributes to the pathogenesis of endometriosis by triggering proinflammatory cytokines and angiogenic growth factors. Journal of Immunology 195 2591–2600. (https://doi.org/10.4049/jimmunol.1501138)


Palmer MT & Weaver CT 2010 Autoimmunity: increasing suspects in the CD4+ T cell lineage. Nature Immunology 11 36–40. (https://doi.org/10.1038/ni.1802)


Received in final form 4 January 2018
Accepted 11 January 2018
Accepted Preprint published online 12 January 2018